Back to Press-Releases
DIA 2014 50th Annual Meeting to Explore Case Studies of Collaboration to Streamline Drug Development
Forum will present ideas and examples for innovation at industry research sites
Leaders in industry and research will examine the challenges and solutions in collaboration to streamline drug development at the DIA 2014 50th Annual Meeting at the San Diego Convention Center from June 15 to 19. “Collaborating to Streamline Drug Development: Case Studies of What Works (and What Doesn’t),” at 1:30 p.m. on June 17, will provide real-world examples of successful and not-so-successful industry-led research collaboration to bring greater efficiency to the drug development process.
Obstacles to industry research collaboration include the slow enrollment of investigators and participants, limited sharing of data across trials and the cost and time required to develop a new drug. The session will feature worldwide experts from prominent collaborative arenas providing insight into how industry partners can work together to reduce the length and costs of the development cycle and enhance the quality of its outcomes.
“As recruiting and sustaining investigators remains a priority for industry research, the session will examine successful collaboration and discuss ideas for increasing participation in clinical development,” said Barbara L. Kunz, DIA global chief executive. “Global leaders will also explore the impact of new models of health care delivery, such as electronic medical records, that could potentially impact collaboration.”
Leaders in industry and research will examine the challenges and solutions in collaboration to streamline drug development at the DIA 2014 50th Annual Meeting at the San Diego Convention Center from June 15 to 19. “Collaborating to Streamline Drug Development: Case Studies of What Works (and What Doesn’t),” at 1:30 p.m. on June 17, will provide real-world examples of successful and not-so-successful industry-led research collaboration to bring greater efficiency to the drug development process.
Obstacles to industry research collaboration include the slow enrollment of investigators and participants, limited sharing of data across trials and the cost and time required to develop a new drug. The session will feature worldwide experts from prominent collaborative arenas providing insight into how industry partners can work together to reduce the length and costs of the development cycle and enhance the quality of its outcomes.
“As recruiting and sustaining investigators remains a priority for industry research, the session will examine successful collaboration and discuss ideas for increasing participation in clinical development,” said Barbara L. Kunz, DIA global chief executive. “Global leaders will also explore the impact of new models of health care delivery, such as electronic medical records, that could potentially impact collaboration.”
Chaired by Douglas Peddicord, executive director of the Association of Clinical Research Organizations, the forum will feature presentations by Dalvir Gill, CEO for TransCelerate Biopharma Inc.; Christine Pierre, founder and president of the Society for Clinical Research Sites; Pamela Tenaerts, executive director of the Clinical Trials Transformation Initiative; and Ann Meeker-O’Connell, senior director for Janssen Pharmaceuticals, Inc.
Contact: Tiffany Cohen
+1.202.499.4411
tcohen@reingold.com
###
×
